Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva Ends Oncology, Women’s Health R&D Following Strategic Review

Oct 06 2014

• By Jessica Merrill

Related Content

Novartis Thinks It Can Do Better With GSK’s Oncologics Than GSK Did

Apr 28 2014

Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?

Jan 31 2014

Teva Shoots For Top Three In Pain And Respiratory

Aug 04 2014

Teva’s Final Copaxone Firewall Is Complexity Of ANDA Review After Court Tosses Patent

Jul 26 2013

Related Companies

Teva Pharmaceutical Industries Ltd.

Cephalon, Inc.

GSK plc

Novartis AG

Additional Topics

Strategy Business Strategies BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window